237 related articles for article (PubMed ID: 24343700)
21. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
[TBL] [Abstract][Full Text] [Related]
22. The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing's sarcoma cell line.
Marx C; Marx-Blümel L; Lindig N; Thierbach R; Hoelzer D; Becker S; Wittig S; Lehmann R; Slevogt H; Heinzel T; Wang ZQ; Beck JF; Sonnemann J
Invest New Drugs; 2018 Jun; 36(3):396-406. PubMed ID: 29150734
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Wells CE; Bhaskara S; Stengel KR; Zhao Y; Sirbu B; Chagot B; Cortez D; Khabele D; Chazin WJ; Cooper A; Jacques V; Rusche J; Eischen CM; McGirt LY; Hiebert SW
PLoS One; 2013; 8(7):e68915. PubMed ID: 23894374
[TBL] [Abstract][Full Text] [Related]
24. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Umamaheswari A; Puratchikody A; Hari N
Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
[TBL] [Abstract][Full Text] [Related]
26. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol-mediated apoptosis of hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation.
Frazzi R; Valli R; Tamagnini I; Casali B; Latruffe N; Merli F
Int J Cancer; 2013 Mar; 132(5):1013-21. PubMed ID: 22833338
[TBL] [Abstract][Full Text] [Related]
28. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.
Scuto A; Kirschbaum M; Buettner R; Kujawski M; Cermak JM; Atadja P; Jove R
Cell Death Dis; 2013 May; 4(5):e635. PubMed ID: 23681230
[TBL] [Abstract][Full Text] [Related]
29. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
Sung JJ; Ververis K; Karagiannis TC
J Photochem Photobiol B; 2014 Feb; 131():104-12. PubMed ID: 24518645
[TBL] [Abstract][Full Text] [Related]
32. Measurement of the cellular deacetylase activity of SIRT1 on p53 via LanthaScreen® technology.
Robers MB; Loh C; Carlson CB; Yang H; Frey EA; Hermanson SB; Bi K
Mol Biosyst; 2011 Jan; 7(1):59-66. PubMed ID: 20931131
[TBL] [Abstract][Full Text] [Related]
33. Expression of the significance of silent information regulator type-1 in Angioimmunoblastic T-cell lymphoma is greater association with tumorigenesis and has strong implications for adverse prognosis.
Ren Y; Gu Y; Wang W; Wang J; Li X; Wang Y; Gao H; Dong X; Tian Y
Cell Cycle; 2016 Jun; 15(12):1545-51. PubMed ID: 27124741
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
35. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation.
Hirai S; Endo S; Saito R; Hirose M; Ueno T; Suzuki H; Yamato K; Abei M; Hyodo I
PLoS One; 2014; 9(7):e102831. PubMed ID: 25033286
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms.
Beier UH; Wang L; Han R; Akimova T; Liu Y; Hancock WW
Sci Signal; 2012 Jun; 5(229):ra45. PubMed ID: 22715468
[TBL] [Abstract][Full Text] [Related]
38. Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.
Chen L; Ahmad N; Liu X
Cell Cycle; 2016; 15(6):840-9. PubMed ID: 26900800
[TBL] [Abstract][Full Text] [Related]
39. Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins.
Botta G; De Santis LP; Saladino R
Curr Med Chem; 2012; 19(34):5871-84. PubMed ID: 22998567
[TBL] [Abstract][Full Text] [Related]
40. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]